Mark Cragg

As a cancer immunologist, Mark Cragg's research uncovers how the immune system interacts with cancer cells and how it can be harnessed in the form of immunotherapy to treat malignancy; particularly by using drugs called monoclonal antibodies. Underpinning this biology are a family of receptors called Fc receptors which serve as a link between the antibodies and the immune cells.  Adopting a multi-disciplinary approach, his research group interacts widely with other members of Cancer Sciences, the Faculty of Medicine, the University, and colleagues in academia and industry, both nationally and internationally.